biostudies-literatureUnknown64Kravutske H<h4>Purpose</h4>Investigating real-world outcomes of moderately hypofractionated radiotherapy (hypoRT) in elderly and multimorbid stage IIB-IIIC non-small-cell lung cancer (NSCLC) patients ineligible for concurrent chemoradiation.<h4>Methods</h4>We retrospectively analysed 70 patients with primary or recurrent stage IIB-IIIC NSCLC (TNM, 8th edition). HypoRT was administered to a total dose of 38-56 Gy in 10-17 fractions (2.5-3.8 Gy/fraction). Patterns of recurrence, survival outcome, and toxicity were assessed.<h4>Results</h4>Seventy patients, with a median age of 76.4 years (range: 51.6-88.2 years), who received hypoRT between August 2015 and September 2022, were reviewed. At baseline, the median Charlson Comorbidity Index (CCI) with oncological diagnosis was 8 (range: 3-13). With a mediaActa oncologica (Stockholm, Sweden)957-965https://www.ebi.ac.uk/biostudies/studies/S-EPMC12308537biostudies-literatureReal-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study.PMC12308537Tufman AKravutske HKauffmann-Guerrero DMansoorian SKasmann LManapov FRichlitzki CSchmidt-Hegemann NSReinmuth NDinkel JEze CLehmann JBelka CGaus RfalseReal-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study.<h4>Purpose</h4>Investigating real-world outcomes of moderately hypofractionated radiotherapy (hypoRT) in elderly and multimorbid stage IIB-IIIC non-small-cell lung cancer (NSCLC) patients ineligible for concurrent chemoradiation.<h4>Methods</h4>We retrospectively analysed 70 patients with primary or recurrent stage IIB-IIIC NSCLC (TNM, 8th edition). HypoRT was administered to a total dose of 38-56 Gy in 10-17 fractions (2.5-3.8 Gy/fraction). Patterns of recurrence, survival outcome, and toxicity were assessed.<h4>Results</h4>Seventy patients, with a median age of 76.4 years (range: 51.6-88.2 years), who received hypoRT between August 2015 and September 2022, were reviewed. At baseline, the median Charlson Comorbidity Index (CCI) with oncological diagnosis was 8 (range: 3-13). With a media2025-01-01T00:00:00Z2025 Jul2026-03-17T15:51:07.896Z2025-08-17T03:05:52.732ZS-EPMC123085374070948110.2340/1651-226X.2025.43496